Using flow cytometry assay to assess the number of CD138+ cells, we found that overexpression of GITR significantly improved the Bortezomib-induced MM tumor inhibition comparing to the control group after 4 weeks treatment with Bortezomib (Fig 6B and S4 Fig). Here, SDC1 is linked to neoplasm.